Key Financial Performance (Consolidated) - Q1 FY27 vs Q1 FY26

  • Revenue from Operations: ₹876.45 million (vs ₹725.86 million) - 20.7% YoY growth
  • Total Revenue: ₹887.33 million (vs ₹734.92 million) - 20.7% YoY growth
  • EBITDA: ₹315.3 million (vs ₹246.56 million) - 27.9% YoY growth
  • EBITDA Margin: 36.0% (vs 34.0%)
  • Profit Before Tax: ₹165.26 million (vs ₹124.69 million) - 32.5% YoY growth
  • Profit Before Tax Margin: 18.85% (vs 17.2%)
  • Profit After Tax: ₹128.45 million (vs ₹91.75 million) - 40.0% YoY growth
  • PAT Margin: 14.7% (vs 12.6%)
  • EPS: ₹2.50 (vs ₹1.80)

Q1 FY27 vs Q4 FY26 Performance

  • Total Revenue growth of 7.9% QoQ (₹821.97 million to ₹887.33 million)
  • EBITDA growth of 25.3% QoQ (₹251.55 million to ₹315.3 million)
  • EBITDA Margin expansion from 30.9% to 36.0%
  • PAT growth of 108.5% QoQ (₹61.59 million to ₹128.45 million)
  • PAT Margin expansion from 7.6% to 14.7%

Cost Structure Analysis (Q1 FY27)

  • Cost of Material Consumed: ₹99.95 million
  • Employee Benefit Expenses: ₹144.1 million
  • Other Expenses: ₹328.5 million
  • Depreciation: ₹112.82 million
  • Finance Cost: ₹37.22 million
  • Tax: ₹36.81 million

Operational Metrics and Expansion

  • Network expansion: 1 hub and 3 spoke centers commissioned during Q1 FY27
  • Additional expansion in July-August 2026: 2 hubs and 3 spoke centers
  • Geographic expansion into Jharkhand with hub center at Dhanbad
  • Upcoming expansion: Tripura hub to follow shortly

Genomics Business Performance

  • Suraksha Genomics revenue: ₹13.7 million in Q1 FY27
  • Year-on-year growth: 136%
  • Five consecutive quarters of sequential growth averaging ~24%
  • Services include prenatal diagnostics, inherited disease testing, whole exome sequencing, pharmacogenomics, and oncology molecular panels

Full Year FY26 Financial Performance

  • Total Revenue: ₹3,135.78 million
  • EBITDA: ₹985.58 million (31.8% margin)
  • PAT: ₹314.04 million (10.1% margin)
  • EPS: ₹6.18

Expansion Plans for FY27

  • Greater Kolkata: 1 spoke center upcoming
  • Rest of Bengal: 1 hub and 5 spokes upcoming (already launched 1 hub and 4 spokes)
  • Jharkhand: 1 hub upcoming (already launched 1 hub)
  • Tripura: 1 hub upcoming
  • Assam: 1 spoke upcoming (already launched 1 spoke)
  • Bihar: 1 hub upcoming
  • Total Launched in FY27: 3 hubs and 6 spokes
  • Total Upcoming in FY27: 4 hubs and 7 spokes

Management Commentary

Ritu Mittal, Joint Managing Director & CEO stated: "Suraksha has begun FY27 on a strong footing. We have delivered YoY growth of 21% with an EBIDTA margin of 36.0% and PAT of 14.7% in Q1 FY27. Network expansion continued through the quarter with one hub and three spoke centres commissioned during Q1 FY27. We have carried this momentum into the current quarter, adding two hubs and three spoke centres in July and August. We have also extended our footprint beyond West Bengal, commissioning a hub centre in neighbouring Jharkhand, with a hub in Tripura to follow shortly. Suraksha Genomics has grown to ₹13.7 million in Q1 FY27, up 136% year-on-year with five consecutive quarters of sequential growth — a small base today, but one we expect to become a meaningful pillar of the business."

Business Model and Strategy

  • Hub & Spoke operating model with demonstrated success in Kolkata region
  • Well-equipped clinical infrastructure including 3T MRI, CT suites, and day-care facilities
  • Customer-centric approach with online bookings, home collection, SMS alerts, and polyclinic chambers
  • LIMS integration, RIS and PACS workflow, advanced imaging tools, and ERP-enabled operations
  • Strategy includes organic expansion, geographic reach extension, selective acquisitions, technology leverage, and B2B partnerships

Historical Financial Trend (FY23-FY26)

  • Revenue growth from ₹1,936.87 million (FY23) to ₹3,135.78 million (FY26)
  • EBITDA growth from ₹474.49 million (FY23) to ₹985.58 million (FY26)
  • PAT growth from ₹60.65 million (FY23) to ₹314.04 million (FY26)
  • Consistent margin expansion across periods

Shareholding Pattern

As of 30 June 2026, shareholding includes Promoters & Promoter Group, FIIs, DIIs (Mutual Funds, AIFs, Central/State governments), and Others (Retail, NRIs, Bodies Corporate).